Physician profile
Kristy Day
NPI 1750804001
$1,429.44
in general payments reported to CMS, 2019-2025
17 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2023: $465 · 2024: $422 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $250.54 | 2023-2025 | Trintellix |
| Novo Nordisk INC | $163.45 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $148.19 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.25 | 2023-2025 | Jardiance, Synjardy |
| Corium, LLC | $107.17 | 2023 | Azstarys |
| Axsome Therapeutics, INC. | $106.13 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.76 | 2025 | Caplyta |
| Lilly USA, LLC | $92.35 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $81.23 | 2023-2025 | |
| Astellas Pharma US INC | $56.11 | 2024-2025 | Veozah |
| Biotronik INC. | $54.76 | 2021 | |
| Genentech USA, INC. | $35.06 | 2021 | |
| Glaxosmithkline, LLC. | $30.17 | 2023 | Trelegy Ellipta |
| Abbott Laboratories | $19.16 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.13 | 2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $15.31 | 2024 | Voquezna |
| Evoke Pharma, INC. | $13.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristy Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.